Repository: UIHistories Project: Board of Trustees Minutes - 1954 [PAGE 391]

EXTRACTED TEXT FROM PAGE:

388

BOARD OF TRUSTEES

[September 24

Assembly, as guests of the Board of Trustees, were taken on an inspection tour of University operations at the Chicago Undergraduate Division and at the Chicago Professional Colleges. At a dinner meeting in the evening, at the suggestion of President Livingston, President Stoddard spoke briefly about the future of the University of Illinois in Chicago with special reference to the desirability of establishing a full four-year undergraduate program. At the request of President Livingston, President Stoddard extended the remarks he made on September 12, for the information of all members of the Board. A copy of his presentation was filed with the Secretary of the Board for record. President Livingston then introduced Representative Paul Randolph of the Twenty-ninth Senatorial District, General Assembly of Illinois, who participated in the inspection tour on September 12 and who was a guest of the Board at the meeting on September 24, to speak. Mr. Randolph spoke briefly on the establishment of a full four-year undergraduate program in Chicago and expressed his appreciation of the University's interest in such a development.

KREBIOZEN RESEARCH

President Stoddard presented the following report:

In view of the nation-wide controversy that followed Dr. A. C. Ivy's announcement of the possible value of Krebiozen in the treatment and management of cancer, the President of the University submitted the following statement to the Board of Trustees on November 23, 1951: "As I see it, the main question now is to determine definitely the value of the drug under research and clinical conditions. "Dr. Ivy has a large number of new cases that need study and evaluation; he needs a few months' time for this and I feel he should be asked to work intensively on this report. "If the problem is regarded as basically an administrative matter, I shall proceed to get the answers that are needed: "(1) To validate to the satisfaction of all concerned the effects of Krebiozen on cancer patients. "(2) To consider questions raised by members of the medical profession as to procedure and future developments. "(3) As soon as may be feasible, to give the public full information on the outcome of the work." Subsequently, Dr. Ivy was granted a leave of absence for two months, beginning January I, 1952, from his duties as Vice-President of the University and I appointed a Research Validation Committee to pass upon Dr. Ivy's available clinical studies of the effects of the drug. The composition of this Committee was as follows: Dr. Warren H. Cole, Chairman Head, Department of Surgery, University of Illinois Dr. N. C. Gilbert Professor Emeritus of Medicine, Northwestern University Dr. Fred Hodges Professor and Chairman of the Department of Roentgenology, University of Michigan Medical School Dr. Robert W. Keeton Professor Emeritus of Medicine, University of Illinois Dr. Paul Steiner Professor of Pathology, University of Chicago Dr. Owen H. Wangensteen Surgeon in Chief, University Hospital, University of Minnesota After an unavoidable delay, Dr. Ivy submitted to the Research Validation Committee on June 13, 1952, his report on the available cases of cancer patients